CONNECT WITH US
HealthTech

HealthTech

Roche’s changing plans show how MFN is complicating European drug launches

Endpoints News logo

Published on

Add as a preferred source on Google
Roche’s changing plans show how MFN is complicating European drug launches

President Donald Trump unveils nine new agreements with drugmakers on August 31. AP Photo/Jacquelyn Martin

Roche will seek Eu­ro­pean ap­proval for its promis­ing new breast can­cer pill giredestrant lat­er than it once ex­pect­ed, high­light­ing how US drug pric­ing pres­sure may …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Be­yond the can­cer vac­cine, how did Mer­ck’s on­col­o­gy pipeline do at ES­MO? October 26, 2026

As­traZeneca's two-pill com­bo may ex­tend Tagris­so's life in lung can­cer October 25, 2026

Pfiz­er looks be­yond lung can­cer flop as BioN­Tech, Bris­tol My­ers show ear­ly ac­tiv­i­ty October 25, 2026

BioN­Tech, Du­al­i­ty­Bio pon­der next steps for HER2 ADC af­ter 'mod­est' breast can­cer re­sults

Mer­ck and Mod­er­na's can­cer vac­cine da­ta were 'a tri­umph of sci­ence.' And now, the work be­gins

Roche takes vic­to­ry lap with lung can­cer pil­l's win over Am­gen, Bris­tol My­ers

Swiss biotech Wind­ward Bio files for Nas­daq IPO to fund Chi­na-de­rived as­sets and in-house R&D



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.